NCT05455827 is a NA clinical trial of fMRI neurofeedback (A) in Depression, sponsored by Brighton & Sussex Medical School.

Who is sponsoring NCT05455827?

NCT05455827 is sponsored by Brighton & Sussex Medical School.

What drugs are being tested in NCT05455827?

Interventions in NCT05455827: fMRI neurofeedback (A), fMRI neurofeedback (B).

What condition does NCT05455827 study?

NCT05455827 studies Depression.

Is NCT05455827 still recruiting?

NCT05455827 is currently completed. Last updated 7 August 2024.

Last reviewed 2024-08-07 · How we verify

NCT05455827

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Using Functional MRI Neurofeedback to Modulate Self-blame in Major Depressive Disorder

Completed NA Last updated 7 August 2024

What this trial tests

NA trial testing fMRI neurofeedback (A) in Depression in 20 participants. Completed in 1 August 2024.

Timeline

28 February 2023

Primary endpoint
1 August 2024

1 August 2024

Quick facts

Lead sponsor	Brighton & Sussex Medical School
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	20
Start date	28 February 2023
Primary completion	1 August 2024
Estimated completion	1 August 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

fMRI neurofeedback (A)
fMRI neurofeedback (B)

Conditions studied

Depression — all drugs for Depression →

Sponsor

Brighton & Sussex Medical School

Who can join

18 and older, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the feasibility of functional MRI neurofeedback in reducing overgeneralised self-blame in patients with depression

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Depression

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05455827 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brighton & Sussex Medical School
Last refreshed: 7 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05455827.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing